Inhibition of cell proliferation and dihydrofolate reductase by liposomes containing methotrexate-dimyristoylphosphatidylethanolamine derivatives and by the glycerophosphorylethanolamine analogs.
Liposomes, which were prepared with the three methotrexate (MTX)-dimyristoylphosphatidylethanolamine (DMPE) derivatives described in the preceding paper, were tested for their ability to block proliferation of mouse 3T3 and L1210 cells. Tritiated deoxyuridine incorporation into DNA could be completely inhibited by liposomes sensitized with MTX-DMPE I (MTX-gamma-DMPE). Under similar conditions, liposomes containing MTX-DMPE II (MTX-alpha-DMPE) and MTX-DMPE III (MTX-alpha, gamma-diDMPE) produced partial and no inhibition, respectively. These effects on cell growth were paralleled by the capacity of liposomes, prepared with each of the DMPE derivatives, to inhibit dihydrofolate reductase isolated from L1210 cells. Analogous experiments with the three corresponding glycerophosphorylethanolamine (glyceroPE) analogs also indicated that MTX-glyceroPE I was the most effective inhibitor of both cell proliferation and enzymatic activity. However, MTX-DMPE I sensitized liposomes apparently enter target cells as a consequence of phagocytosis, and not via the ubiquitous methotrexate transport system that is employed by MTX-glyceroPE I. For example, novel use of thiamine pyrophosphate showed that this compound had no influence on inhibition of cell proliferation due to liposomes, whereas thiamine pyrophosphate could completely antagonize the inhibitory effects of methotrexate and MTX-glyceroPE I. The results are discussed with reference to possible therapeutic advantages of these liposomes.
D000643:Ammonium Chloride / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport; D002455:Cell Division / Q000187:drug effects*; D055598:Chemical Phenomena; D002621:Chemistry; D004247:DNA / Q000096:biosynthesis; D003857:Deoxyuridine / Q000378:metabolism; D005493:Folic Acid Antagonists; D066298:In Vitro Techniques; D007939:Leukemia L1210 / Q000378:metabolism; D008081:Liposomes / Q000008:administration & dosage*; D008727:Methotrexate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D013835:Thiamine Pyrophosphate / Q000494:pharmacology
D005493:Folic Acid Antagonists; D008081:Liposomes; D010714:Phosphatidylethanolamines; D000643:Ammonium Chloride; C002449:glycerophosphoethanolamine; D004247:DNA; D013835:Thiamine Pyrophosphate; D003857:Deoxyuridine; D008727:Methotrexate; C018525:1,2-dimyristoylphosphatidylethanolamine